Abstract

Sabra Health Care will report results on April 29, 2026 Post Market; our preview summarizes consensus for revenue, gross margin, net profitability, and adjusted EPS alongside business-mix dynamics and analyst positioning.

Market Forecast

The market’s current baseline anticipates Sabra Health Care to generate approximately 200.05 million US dollars in revenue this quarter, implying 12.15% year-over-year growth; EBIT is projected at 81.75 million US dollars with 20.62% year-over-year growth, and adjusted EPS is forecast at 0.17 with a year-over-year change of -1.10%. Company-level margin guidance is not explicitly stated for the quarter, but consensus implies stable to modestly improving profitability through EBIT leverage; if realized, revenue acceleration and EBIT outperformance would be the focal points.

Sabra Health Care’s portfolio mix is anchored by rental and related revenue and resident fees and services, with the former accounting for 374.13 million US dollars and the latter 356.88 million US dollars in the latest disclosed period, while interest and other contributed 43.62 million US dollars; this positions earnings sensitivity primarily to occupancy stabilization and rent escalators. The most promising area is EBIT growth, where the forecasted 81.75 million US dollars implies a 20.62% year-over-year expansion, supported by improved operating performance across key tenants and better lease economics.

Last Quarter Review

In the last reported quarter, Sabra Health Care delivered revenue of 211.90 million US dollars, a gross profit margin of 62.04%, GAAP net profit attributable to the parent company of 27.23 million US dollars, a net profit margin of 12.92%, and adjusted EPS of 0.11, with revenue growing 16.21% year over year and adjusted EPS declining 42.11% year over year.

A notable highlight was revenue outperformance versus expectations, with top line reaching 211.90 million US dollars against a lower market estimate and achieving 16.21% year-over-year growth, while EBIT of 63.93 million US dollars trailed the prior expectation, signaling some cost drag despite strong sales. By business line, rental and related revenue represented 374.13 million US dollars in the trailing period and resident fees and services contributed 356.88 million US dollars, underscoring the balance between triple-net lease income and operating exposure within the portfolio.

Current Quarter Outlook (with major analytical insights)

Main business trajectory and revenue quality

The primary driver of Sabra Health Care’s consolidated revenue remains its contractual rental stream, complemented by resident fees and services tied to operating exposure in senior housing and related care. With revenue projected at 200.05 million US dollars this quarter, year-over-year growth of 12.15% implies continued normalization in occupancy and incremental rent escalations. Given the last quarter’s 62.04% gross margin and 12.92% net margin, investors will evaluate whether revenue growth translates to margin stability amid labor cost dynamics and operator health. The quarter’s setup suggests a focus on revenue durability: tenant coverage ratios, renegotiated leases where applicable, and incremental dispositions or acquisitions that could shift the mix between rental stability and operating volatility.

EBIT expansion and margin pathway

Consensus EBIT of 81.75 million US dollars implies 20.62% year-over-year growth, outpacing revenue and signaling operating leverage. This spread suggests benefits from portfolio-level efficiencies and incrementally stronger performance in the operating segments, possibly aided by cost normalization in staffing and more stable occupancy patterns. Investors will scrutinize whether EBIT gains are sustainable given recent variability—last quarter’s EBIT of 63.93 million US dollars fell short of expectations—so the key will be translating stronger top-line trends into consistent operating margin improvement. If EBIT tracks the current projection, the narrative pivots to ongoing recovery momentum and validates a path to more resilient cash flow coverage.

Adjusted EPS sensitivity and capital structure factors

Adjusted EPS is forecast at 0.17, reflecting a slight year-over-year decline of 1.10%, despite predicted revenue and EBIT growth. The EPS setup indicates potential headwinds from interest expense or non-operating items that may partially offset operating gains, along with possible share count effects. With the prior quarter’s adjusted EPS at 0.11, investors will watch whether improved EBIT conversion narrows the gap to EPS, especially as financing conditions remain tighter than pre-2022 norms. Any commentary regarding debt refinancing, laddering, or asset recycling will be watched closely for EPS and AFFO implications in subsequent quarters.

Segment dynamics and the most promising growth area

Within Sabra Health Care’s revenue base, the rental and related line is a stabilizer for cash flows, while resident fees and services provide cyclical upside as operating metrics improve. The most promising growth signal this quarter is the projected 20.62% year-over-year growth in EBIT to 81.75 million US dollars, which, if achieved, demonstrates expanding operating leverage even as adjusted EPS faces minor pressure. The portfolio’s recent revenue strength supports the view that occupancy and rate actions are filtering through to operating results; sustaining this trend could enable further improvement in coverage metrics and valuation multiples.

Key stock price drivers and risk balance

The stock’s reaction will likely be driven by whether EBIT meets or exceeds projections while adjusted EPS matches the modestly conservative outlook. A clean beat on EBIT with stable gross margins near the recent 62.04% level could offset EPS softness and support a constructive share response. Conversely, any repeat of last quarter’s EBIT shortfall would refocus the market on cost and operator variability, especially if revenue still tracks consensus. The interplay between margin progression and financing costs remains central: updates on liability management and capital deployment—including dispositions or reinvestments—could influence sentiment more than revenue alone.

Analyst Opinions

Across recent commentary, the majority tone appears neutral-to-cautious rather than outright bullish, with at least one institution reaffirming a Hold stance and a 20.00 US dollars price target. The Hold positioning reflects an expectation of balanced risk and reward into the print: revenue and EBIT momentum are acknowledged, but EPS headwinds and the need to demonstrate consistent margin execution temper enthusiasm. This perspective suggests that upside in shares will require evidence of sustained EBIT leverage translating into per-share earnings resilience, along with clarity on capital structure optimization and disciplined portfolio actions aligned to coverage improvement.